Csizmar, Clifford M. https://orcid.org/0000-0002-1221-8854
Natu, Anuya
Gurney, Mark https://orcid.org/0000-0002-7062-2644
Fathima, Saubia https://orcid.org/0000-0002-9979-7923
Alsugair, Ali Khalid A.
Kanagal-Shamanna, Rashmi https://orcid.org/0000-0001-7829-5249
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Bazinet, Alexandre
Chien, Kelly https://orcid.org/0000-0001-6024-1613
Hammond, Danielle https://orcid.org/0000-0002-6017-2264
DiNardo, Courtney https://orcid.org/0000-0001-9003-0390
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
Ravandi-Kashani, Farhad https://orcid.org/0000-0002-7621-377X
Pemmaraju, Naveen https://orcid.org/0000-0002-1670-6513
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Lasho, Terra L.
Finke, Christy M.
Al-Kali, Aref
Alkhateeb, Hassan https://orcid.org/0000-0002-3609-8404
Begna, Kebede https://orcid.org/0000-0003-2730-8593
Gangat, Naseema
Hefazi Torghabeh, Mehrdad https://orcid.org/0000-0001-8860-3380
Matin, Aasiya
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Saliba, Antoine N. https://orcid.org/0000-0001-5134-7336
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Kantarjian, Hagop M.
Komrokji, Rami S. https://orcid.org/0000-0002-1876-5269
Xie, Zhuoer https://orcid.org/0000-0003-1266-9804
Ali, Najla A.
Sallman, David https://orcid.org/0000-0003-0504-8233
Padron, Eric https://orcid.org/0000-0002-4707-7916
Montalban-Bravo, Guillermo https://orcid.org/0000-0002-4533-5176
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Article History
Received: 19 March 2025
Revised: 2 May 2025
Accepted: 14 May 2025
First Online: 24 June 2025
Competing interests
: MMP has received research funding from Kura Oncology, Stem Line, Epigenetix, Polaris and has served on the advisory board for CTI pharmaceuticals.
: This retrospective study was approved by the Institutional Review Boards (IRB) at each center. The IRBs deemed this study to be minimal risk and thus exempt from written informed consent.